The New York Statewide HCCN (NYS-HCCN) at CHCANYS
HCCN Infographic

Established in 2012, the New York Statewide Health Center Controlled Network (NYS-HCCN) is one of forty-nine HRSA funded networks that work together to strengthen and leverage health information technology (HIT).

Benefits & Eligibility
AmeriCorps Members

CHCANYS Public Health AmeriCorps is a partnership and collaboration between CHCANYS, the New York State Commission on National and Community Service, AmeriCorps, and the CDC.

Resources on workforce & human resources
Workforce

Various online resources compiled to provide health centers with valuable information and training and technical assistance on workforce, human resources, and National Health Services Corps Programs and other health workforce related resources.

,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
RESOURCES AND RELATED EVENTS
Data Analytics

Data Analytics is the act of extracting and organizing raw data in order to identify patterns and make inferences.

Current:

HCCN Infographic
Join CHCANYS AmeriCorps
Workforce
UDS+

HRSA Decries Pharma Actions on 340B Contract Pharmacies; Calls for Refunds to 340B Covered Entities

On May 17, HRSA sent letters to six pharmaceutical manufacturers stating that:

  • Their refusal to ship 340B-priced drugs to contract pharmacies is a direct violation of the 340B statute. 
  • They must immediately resume shipping 340B-priced drugs to contract pharmacies.
  • They must credit or refund all 340B providers for overcharges that resulted from their policy; it is the manufacturers’ responsibility to contract the 340B providers and purse “mutually agreed upon refund arrangements.”
  • If manufacturers continue to refuse to ship 340B-priced drugs to contract pharmacies, this “may” result in HHS imposing Civil Monetary Penalties on them, not to exceed $5,000 for each instance of overcharging. 
  • Manufacturers must provide HHS with an update on their plans to resume shipping 340B-priced drugs to contract pharmacies by June 1.

It remains to be seen how pharmaceutical manufacturers will respond to the HHS letters. It is very possible that they will pursue further litigation. CHCANYS will continue to work closely with NACHC and our partner PCAs to protect the 340B program.

Published on